Tislelizumab
- Generic Name
- Tislelizumab
- Brand Names
- Tevimbra, Tizveni
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1858168-59-8
- Unique Ingredient Identifier
- 0KVO411B3N
- Background
Tislelizumab is under investigation in clinical trial NCT02660034 (The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Subjects With Advanced Solid Tumors).
- Indication
⑴用于治疗至少经过二线系统化疗的复发或难治性经典型霍奇金淋巴瘤（R/R cHL）患者。
⑵用于治疗局部晚期或转移性尿路上皮癌。
⑶联合化疗用于治疗一线晚期非鳞状非小细胞肺癌（NSCLC）患者。
⑷用于治疗既往接受过治疗的不可切除肝细胞癌患者。
⑸用于治疗晚期恶性实体瘤
- Associated Conditions
- -
- Associated Therapies
- -
A Study Evaluating the Efficacy and Safety of Tislelizumab Versus Chemotherapy in Advanced Non-Squamous Non-small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-09-10
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 334
- Registration Number
- NCT03663205
- Locations
- 🇨🇳
Daping Hospital, Third Military Medical University, Chongqing, Chongqing, China
🇨🇳Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
🇨🇳Yunnan Cancer Hospital, Kunming, Yunnan, China
A Study of Tislelizumab in Combination With Chemotherapy Versus Chemotherapy in Advanced Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-07-20
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 360
- Registration Number
- NCT03594747
- Locations
- 🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China
🇨🇳Beijing Chest Hospital,Capital Medical University, Beijing, Beijing, China
🇨🇳Anhui Provincial Hospital, Hefei, Anhui, China
Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms
- Conditions
- Extranodal NK/T-cell Lymphoma, Nasal TypeAngioimmunoblastic T-Cell Lymphoma RecurrentAngioimmunoblastic T-Cell Lymphoma RefractoryPeripheral T-Cell Lymphoma RefractoryAnaplastic Large Cell Lymphoma, ALK-PositiveAnaplastic Large Cell Lymphoma, ALK-negativePeripheral T Cell LymphomaAdult Nasal Type Extranodal NK/T-cell LymphomaPTCLExtranodal NK/T-cell Lymphoma
- Interventions
- First Posted Date
- 2018-04-10
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 77
- Registration Number
- NCT03493451
- Locations
- 🇨🇦
British Columbia Cancer Agency the Vancouver Centre, Vancouver, British Columbia, Canada
🇨🇳Sun Yat Sen University Cancer Center, Guangzhou, Guangdong, China
🇨🇳Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China
BGB A317 in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Carcinoma
- First Posted Date
- 2018-03-19
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 30
- Registration Number
- NCT03469557
- Locations
- 🇨🇳
Fifth Medical Center of Pla General Hospital, Beijing, Beijing, China
🇨🇳Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China
🇨🇳Tongji Hospital of Tongji Medical College Huazhong University of Science and Technology, Wuhan, Hubei, China
Anti-PD-1 in Combination With Chemotherapy as First-Line Treatment to Lung Cancer
- First Posted Date
- 2018-02-14
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 54
- Registration Number
- NCT03432598
- Locations
- 🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China
🇨🇳Beijing Chest Hospital, Capital Medical University, Beijing, Beijing, China
🇨🇳Jiangsu Province Hospital, Nanjing, Jiangsu, China
A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2018-02-13
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 512
- Registration Number
- NCT03430843
- Locations
- 🇧🇪
UZ Antwerpen, Antwerp, Belgium
🇨🇳Anhui Medical University - The Second Hospital, Hefei, Anhui, China
🇨🇳The First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, China
Study of BGB-A317 in Participants With Previously Treated Unresectable HCC
- First Posted Date
- 2018-02-05
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 249
- Registration Number
- NCT03419897
- Locations
- 🇨🇳
The Second Hospital of Anhui Medical University, Hefei, Anhui, China
🇨🇳Military Hospital of China, Beijing, Beijing, China
🇨🇳Chinese Pla General Hospital, Beijing, Beijing, China
Phase 3 Study of Tislelizumab Versus Sorafenib in Participants With Unresectable HCC
- Conditions
- Interventions
- First Posted Date
- 2018-01-26
- Last Posted Date
- 2024-01-10
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 674
- Registration Number
- NCT03412773
- Locations
- 🇺🇸
University of California - Hematology and Oncology, Los Angeles, California, United States
🇺🇸Cancer Treatment Centers of America - Oncology, Philadelphia, Pennsylvania, United States
🇺🇸UMass Memorial Medical Center, Worcester, Massachusetts, United States
Comparison of Efficacy and Safety of Anti-PD-1 Antibody BGB-A317 Versus Docetaxel as Treatment in the Second- or Third-line Setting in Participants With NSCLC
- First Posted Date
- 2017-12-02
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 805
- Registration Number
- NCT03358875
- Locations
- 🇨🇳
The First Affiliated Hospital of Xian Jiaotong University, Xian, Shaanxi, China
🇱🇹Hospital of Lithuanian University of Health Sciences Kaunas Clinics Branch Oncology Hospital, Kaunas, Lithuania
🇲🇽Health Pharma Professional Research Sa de Cv, Ciudad de Mexico, Mexico
A Study of Tislelizumab as Monotherapy in Relapsed or Refractory Classical Hodgkin Lymphoma
- First Posted Date
- 2017-07-06
- Last Posted Date
- 2021-11-18
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 70
- Registration Number
- NCT03209973
- Locations
- 🇨🇳
The First Affilliated Hospital of Jilin University, Changchun, Jilin, China
🇨🇳Institute of Hematology and Blood disease hospital,Chinese Academy of Medical Science, Tianjin, Tianjin, China
🇨🇳Beijing Cancer Hospital, Beijing, Beijing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.